the preferred active compounds of the present invention are in an ionized , salt form or as the free base of the pharmaceutically acceptable salts thereof ( provided , for the aerosol or pump spray compositions , they are soluble in the spray solvent ). these compounds are soluble in the non - polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations . these concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa . this aspect of the invention is especially important when there is a large ( 40 - 99 . 99 %) first pass effect . as propellants for the non polar sprays , propane , n - butane , iso - butane , n - pentane , iso - pentane , and neo - pentane , and mixtures thereof may be used . n - butane and iso - butane , as single gases , are the preferred propellants . it is permissible for the propellant to have a water content of no more than 0 . 2 %, typically 0 . 1 - 0 . 2 %. all percentages herein are by weight unless otherwise indicated . it is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds . these contaminants include oxidizing agents , reducing agents , lewis acids or bases , and water . the concentration of each of these should be less than 0 . 1 %, except that water may be as high as 0 . 2 %. suitable non - polar solvents for the capsules and the non - polar sprays include ( c 2 - c 24 ) fatty acid ( c 2 - c 6 ) esters , c 7 - c 18 hydrocarbon ( of linear or branched configuration ), c 2 - c 6 alkanoyl esters , and the triglycerides of the corresponding acids , e . g . c 2 - c 6 carboxylic acids . when the capsule fill is a paste , other liquid components may be used instead of the above low molecular weight solvents . these include soya oil , corn oil , other vegetable oils . as solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols ( peg ) of 400 - 1000 mw ( preferably 400 - 600 ), low molecular weight ( c 2 - c 8 ) mono and polyols and alcohols of c 7 - c 18 linear or branch chain hydrocarbons , glycerin may also be present and water may also be used in the sprays , but only in limited amount in the capsules . it is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell . likewise , there may be some migration of components from the fill to the shell during curing and even throughout the shelf - life of the capsule . therefore , the values given herein are for the compositions as prepared , it being within the scope of the invention that minor variations will occur . the preferred flavoring agents are synthetic or natural oil of peppermint , oil of spearmint , citrus oil , fruit flavors , sweeteners ( sugars , aspartame , saccharin , etc . ), and combinations thereof . the compositions may further include a taste mask . the term “ taste mask ” as used herein means an agent that can hide or minimize an undesirable flavor such as a bitter or sour flavor . a representative taste masks is a combination of vanillin , ethyl vanillin , maltol , iso - amyl acetate , ethyl oxyhydrate , anisic aldehyde , and propylene glycol ( commercially available as “ pfc 9885 bitter mask ” from pharmaceutical flavor clinic of camden , n . j .). a taste mask in combination with a flavoring agent is particularly advantageous when the active compound is an alkaloid since alkaloids often have a bitter taste . the compositions of the invention may also include additional components such as absorption enhancers and antioxidants . examples of suitable absorption enhancers include without limitation oleic acid , 23 - lauryl ether , aprotinin , azone , benzalkonium chloride , cetylpyridinium chloride , cetyltrimethylammonium bromide , cyclodextrin , dextran sulfate , lauric acid , lauric acid / propylene glycol , lysophosphatidylcholine , menthol , methoxysalicylate , methyloleate , phosphatidylcholine , polyoxyethylene , polysorbate 80 , sodium edta ( ethylenediamine tetraacetic acid ), sodium glycocholate , sodium glycodeoxycholate , sodium lauryl sulfate , sodium salicylate , sodium taurocholate , sodium taurodeoxycholate , sulfoxides and various alkyl glycosides . the amount of absorption enhancer that can be included in the compositions of the present invention can be from about 0 . 01 to about 5 w %; preferably from about 0 . 5 to about 4 w % and most preferably from about 1 to about 2 w %. examples of suitable antioxidants include without limitation ascorbyl palmitate , alpha tocopherol , butylated hydroxyanisole and fumaric acid . the amount of antioxidant that can be included in the compositions of the present invention can be from about 0 . 01 to about 20 w %; preferably from about 0 . 5 to about 10 w % or from about 0 . 5 to about 4 w % and most preferably from about 1 to about 2 w %. the active substances include the active compounds selected from the group consisting of cyclosporine , sermorelin , octreotide acetate , calcitonin - salmon , insulin lispro , propofol succinate , clozepine , cyclobenzaprine , dexfenfluramine hydrochloride , glyburide , zidovudine , erythromycin , ciprofloxacin , ondansetron hydrochloride , dimenhydrinate , cimetidine hydrochloride , famotidine , phenyloin sodium , phenyloin , carboprost thromethamine , carboprost , diphenhydramine hydrochloride , isoproterenol hydrochloride , terbutaline sulfate , terbutaline , theophylline , albuterol sulfate and neutraceuticals , that is to say nutrients with pharmacological action such as but not limited to carnitine , valerian , echinacea , and the like . in another embodiment , the active compound is a p - fox ( fatty acid oxidation ) inhibitor , acetylcholinesterase inhibitor , nerve impulse inhibitor , anti - cholinergic , anti - convulsant , anti - psychotic , anxiolytic agent , dopamine metabolism inhibitor , agent to treat post stroke sequelae , neuroprotectant , agent to treat alzheimer &# 39 ; s disease , neurotransmitter , neurotransmitter agonist , sedative , agent for treating attention deficit disorder , agent for treating narcolepsy , central adregenic antagonist , anti - depression agent , agent for treating parkinson &# 39 ; s disease , benzodiazepine antagonist , stimulant , neurotransmitter antagonist , tranquilizer , or a mixture thereof . in one embodiment the active compound is a p - fox inhibitor . a suitable p - fox inhibitor for use in the buccal sprays of the invention includes , but is not limited to , ranolazine . in one embodiment the active compound is an acetylcholinesterase inhibitor . suitable acetylcholinesterase inhibitors for use in the buccal sprays of the invention include , but are not limited to , galantamine , neostigmine , physostigmine , and edrophonium . in one embodiment the active compound is a nerve impulse inhibitor . suitable nerve impulse inhibitors for use in the buccal sprays of the invention include , but are not limited to , levobupivacaine , lidocaine , prilocalne , mepivacaine , propofol , rapacuronium bromide , ropivacaine , tubocurarine , atracurium , doxaurium , mivacurium , pancuronium , vercuronium , pipecuronium , and rocuronium . in one embodiment the active compound is an anti - cholinergic . suitable anti - cholinergics for use in the buccal sprays of the invention include , but are not limited to , amantadine , ipratropium , oxitropium , and dicycloverine . in one embodiment the active compound is an anti - convulsant . suitable anti - convulsants for use in the buccal sprays of the invention include , but are not limited to , acetazolamide , carbamazepine , clonazepam , diazepam , divalproex ( valproic acid ), ethosuximide , lamotrignine acid , levetriacetam , oxcarbazepine , phenobarbital , phenyloin , pregabalin , primidone , remacemide , trimethadione , topiramate , vigabatrin , and zonisamide . in one embodiment the active compound is an anti - psychotic . suitable anti - psychotics for use in the buccal sprays of the invention include , but are not limited to , amisulpride , aripiprazole bifemelane , bromperidol , clozapine , chlorpromazine ; haloperidol , iloperidone loperidone , olanzapine , quetiapine , fluphenazine , fumarate , risperidone , thiothixene , thioridazine , sulpride , and ziprasidone , in one embodiment the active compound is an anxiolytic agent . suitable anxiolytic agents for use in the buccal sprays of the invention include , but are not limited to , amitryptiline , atracurium , buspirone , chlorzoxazone , clorazepate , cisatracurium , cyclobenzaprine , eperisone , esopiclone , hydroxyzine , mirtazapine , mivacurium , pagoclone , sulperide , zaleplon , and zopiclone . in one embodiment the active compound is a dopamine metabolism inhibitor . suitable dopamine metabolism inhibitors for use in the buccal sprays of the invention include , but are not limited to , entacapone , lazebemide , selegiline , and tolcapone . in one embodiment the active compound is an agent to treat post stroke sequelae . suitable agents to treat post stroke sequelae for use in the buccal sprays of the invention include , but are not limited to , glatiramer , interferon beta 1a , interferon beta 1b , estradiol , and progesterone . in one embodiment the active compound is a neuroprotectant . suitable neuroprotectants for use in the buccal sprays of the invention include , but are not limited to , donepezil , memanine , nimodipine , riluzole , rivastigmine , tacrine , tak147 , and xaliproden . in one embodiment the active compound is an agent to treat alzheimer &# 39 ; s disease . suitable agents to treat alzheimer &# 39 ; s disease for use in the buccal sprays of the invention include , but are not limited to , carbidopa , levodopa , tacrine , donezepil , rivastigmine , and galantamine . in one embodiment the active compound is a neurotransmitter . suitable neurotransmitters for use in the buccal sprays of the invention include , but are not limited to , acetylcholine , serotonin , 5 - hydroxytryptamine ( 5 - ht ), gaba , glutamate , aspartate , glycine , histamine , epinephrine , norpinephrine , dopamine , adenosine , atp , and nitric oxide . in one embodiment the active compound is a neurotransmitter agonist . suitable neurotransmitter agonists for use in the buccal sprays of the invention include , but are not limited to , almotriptan , aniracetam , atomoxetine , benserazide , bromocriptine , bupropion , cabergoline , citalopram , clomipramine , desipramine , diazepam , dihydroergotamine , doxepin duloxetine , eletriptan , escitalopram , fluvoxamine , gabapentin , imipramine , moclobemide , naratriptan , nefazodone , nefiracetam acamprosate , nicergoline , nortryptiline , paroxetine , pergolide , pramipexole , rizatriptan , ropinirole , sertraline , sibutramine , propofol , tiagabine , trazodone , venlafaxine , and zolmitriptan . in one embodiment the active compound is a sedative . suitable sedatives for use in the buccal sprays of the invention include , but are not limited to , dexmedetomidine , eszopiclone , indiplon , zolpidem , and zaleplon . in one embodiment the active compound is an agent for treating attention deficit disorder . suitable agents for treating attention deficit disorder for use in the buccal sprays of the invention include , but are not limited to , amphetamine , dextroamphetamine , methylphenidate , and pemoline . in one embodiment the active compound is an agent for treating narcolepsy . suitable agents for treating narcolepsy for use in the buccal sprays of the invention include , but are not limited to , modafinil and mazindol . in one embodiment the active compound is a central adregenic antagonists . a suitable central adregenic antagonists for use in the buccal sprays of the invention includes , but is not limited to , mesoridazine . in one embodiment the active compound is an anti - depression agent . suitable anti - depression agents for use in the buccal sprays of the invention include , but are not limited to , amitriptyline , amoxapine , bupropion , clomipramine , clomipramine , clorgyline , desipramine , doxepin , fluoxetine , imipramine , isocarboxazid , maprotiline , mirtazapine , nefazodone , nortriptyline , paroxetine , phenelzine , protriptyline , sertraline , tranylcypromine , trazodone , and venlafaxine . in one embodiment the active compound is an agent for treating parkinson &# 39 ; s disease . suitable agents for treating parkinson &# 39 ; s disease for use in the buccal sprays of the invention include , but are not limited to , amantadine , bromocriptine , carvidopa , levodopa , pergolide , and selegiline . in one embodiment the active compound is a benzodiazepine antagonist . a suitable benzodiazepine antagonist for use in the buccal sprays of the invention includes , but is not limited to , flumazenil . in one embodiment the active compound is a neurotransmitter antagonist . a suitable neurotransmitter antagonist for use in the buccal sprays of the invention includes , but is not limited , to deramciclane . in one embodiment the active compound is a stimulant . suitable stimulants for use in the buccal sprays of the invention include , but are not limited to , amphetamine , dextroamphetamine , dinoprostone , methylphenidate , methylphenidate , modafinil , and pemoline . in one embodiment the active compound is a tranquilizer . a suitable tranquilizer for use in the buccal sprays of the invention includes , but is not limited to , mesoridazine . in one embodiment , the active compound of the compositions comprises propofol . typically , when the active compound comprises propofol , the buccal spray composition contains propofol in an amount from about 0 . 1 to about 99 . 8 weight percent of the composition ( w %), preferably about 1 to about 95 w % propofol , and more preferably about 5 to about 90 w % propofol . also , the amounts of propofol can range from about 1 to about 80 w %, from about 1 to about 85 w %, from about 5 to about 75 %, from about 10 to about 60 w % or from about 10 to about 70 w %. furthermore , when the buccal spray composition comprises propofol as an active compound , the solvent used in the composition can be a polar solvent , a non - polar solvent or a mixture thereof . also , the buccal spray composition can be propellant free or it can contain a propellant . moreover , the buccal spray composition that contains propofol as an active compound may contain a flavoring and / or masking agent . the invention further relates to a method of administering propofol to a mammal in which the oral mucosa of the mammal is sprayed with a buccal spray composition comprising propofol . the formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof . the term “ pharmaceutically acceptable salts ” refers to salts prepared from pharmaceutically acceptable non - toxic acids or bases including organic and inorganic acids or bases . when an active compound of the present invention is acidic , salts may be prepared from pharmaceutically acceptable non - toxic bases . salts derived from all stable forms of inorganic bases include aluminum , ammonium , calcium , copper , iron , lithium , magnesium , manganese , potassium , sodium , zinc , etc . particularly preferred are the ammonium , calcium , magnesium , potassium , and sodium salts . salts derived from pharmaceutically acceptable organic non - toxic bases include salts of primary , secondary , and tertiary amines , substituted amines including naturally occurring substituted amines , cyclic amines and basic ion - exchange resins such as arginine , betaine , caffeine , choline , n , n dibenzylethylenediamine , diethylamine , 2 - diethylaminoethanol , 2 - dimethyl - aminoethanol , ethanolamine , ethylenediamine , n - ethylmorpholine , n - ethylpiperidine , glucamine , glucosamine , histidine , isopropylamine , lysine , methyl - glucosamine , morpholine , piperazine , piperidine , polyamine resins , procaine , purine , theobromine , triethylamine , trimethylamine , tripropylamine , etc . when an active compound of the present invention is basic , salts may be prepared from pharmaceutically acceptable non - toxic acids . such acids include acetic , benzenesulfonic , benzoic , camphorsulfonic , citric , ethane - sulfonic , fumaric , gluconic , glutamic , hydrobromic , hydrochloric , isethionic , lactic , maleic , mandelic , methanesulfonic , mucic , nitric , pamoic , pantothenic , phosphoric , succinic , sulfuric , tartaric , p - toluenesulfonic , etc . particularly preferred are citric , hydrobromic , maleic , phosphoric , sulfuric , and tartaric acids . in the discussion of methods of treatment herein , reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof . while certain formulations are set forth herein , the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician . the invention is further defined by reference to the following examples , which are intended to be illustrative and not limiting . the following are examples of certain classes . all values unless otherwise specified are in weight percent . most preferred amounts preferred amount amount a . cyclosporine lingual spray cyclosporine 5 - 50 10 - 35 15 - 25 water 5 - 20 7 . 5 - 50 9 . 5 - 12 ethanol 5 - 60 7 . 5 - 50 10 - 20 polyethylene glycol 20 - 60 30 - 45 35 - 40 flavors 0 . 1 - 5 1 - 4 2 - 3 b . cyclosporine non - polar lingual spray cyclosporine 1 - 50 3 - 40 5 - 30 migylol 20 25 30 - 40 polyoxyethylated 20 25 30 - 40 castor oil butane 25 - 80 30 - 70 33 - 50 flavors 0 . 1 - 5 1 - 4 2 - 3 c . cyclosporine non - polar bite capsule cyclosporine 1 - 35 5 - 25 10 - 20 olive oil 25 - 60 35 - 55 30 - 45 polyoxyethylated 25 - 60 35 - 55 30 - 45 oleic glycerides flavors 0 . 1 - 5 1 - 4 2 - 3 d . cyclosporine bite capsule cyclosporine 5 - 50 10 - 35 15 - 25 polyethylene 20 - 60 30 - 45 35 - 40 glycol glycerin 5 - 30 7 . 5 - 25 10 - 20 propylene glycol 5 - 30 7 . 5 - 25 10 - 20 flavors 0 . 1 - 10 1 - 8 3 - 6 e . sermorelin ( as the acetate ) lingual spray sermorelin . 01 - 5 . 1 - 3 . 2 - 1 . 0 ( as the acetate ) mannitol 1 - 25 5 - 20 10 - 15 monobasic sodium 0 . 1 - 5 1 - 3 1 . 5 - 2 . 5 phosphate , dibasic sodium 0 . 01 - 5 . 05 - 3 0 . 1 - 0 . 5 phosphate water ethanol 5 - 30 7 . 5 - 25 9 . 5 - 15 polyethylene glycol 20 - 60 30 - 45 35 - 40 propylene glycol 5 - 25 10 - 20 12 - 17 flavors 0 . 1 - 5 1 - 4 2 - 3 f . octreotide acetate ( sandostatin ) lingual spray octreotide acetate 0 . 001 - 0 . 5 0 . 005 - 0 . 250 0 . 01 - 0 . 10 acetic acid 1 - 10 2 - 8 4 - 6 sodium acetate 1 - 10 2 - 8 4 - 6 sodium chloride 3 - 30 . 5 - 25 15 - 20 flavors 0 . 1 - 5 0 . 5 -. 4 2 - 3 ethanol 5 - 30 7 . 5 - 20 9 . 5 - 15 water 15 - 95 35 - 90 65 - 85 flavors 0 . 1 - 5 1 - 4 2 - 3 g . calcitonin - salmon lingual spray calcitonin - salmon 0 . 001 - 5 0 . 005 - 2 01 - 1 . 5 ethanol 2 - 15 3 - 10 12 7 - 9 . 5 water 30 - 95 50 - 90 60 - 80 polyethylene 2 - 15 3 - 10 7 - 9 . 5 glycol sodium chloride 2 . 5 - 20 5 - 15 10 - 12 . 5 flavors 0 . 1 - 5 1 - 4 2 - 3 h . insulin lispro , lingual spray insulin 20 - 60 4 - 55 5 - 50 glycerin 0 . 1 - 10 0 . 25 - 5 0 . 1 - 1 . 5 dibasic sodium 1 - 15 2 . 5 - 10 4 - 8 phosphate m - cresol , 1 - 25 5 - 25 7 . 5 - 12 . 5 zinc oxide 0 . 01 - 0 . 25 . 05 - 0 . 15 0 . 075 - 0 . 10 m - cresol 0 . 1 - 1 0 . 2 - 0 . 8 0 . 4 - 0 . 6 phenol trace amounts trace amounts trace amounts ethanol 5 - 20 7 . 5 - 15 9 - 12 water 30 - 90 40 - 80 50 - 75 propylene glycol 5 - 20 7 . 5 - 15 9 - 12 flavors 0 . 1 - 5 0 . 5 - 3 0 . 75 - 2 adjust ph to 7 . 0 - 7 . 8 with hci or naoh cns active amines and their salts : including but not limited to tricyclic amines , gaba analogues , thiazides , phenothiazine derivatives , serotonin antagonists and serotonin reuptake inhibitors most preferred amounts preferred amount amount a . sumatriptan succinate lingual spray sumatriptan succinate 0 . 5 - 30 1 - 20 10 - 15 ethanol 5 - 60 7 . 5 - 50 10 - 20 propylene glycol 5 - 30 7 . 5 - 20 10 - 15 polyethylene glycol 0 - 60 30 - 45 35 - 40 water 5 - 30 7 . 5 - 20 10 - 15 flavors 0 . 1 - 5 1 - 4 2 - 3 b . sumatriptan succinate bite capsule sumatriptan succinate 0 . 01 - 5 0 . 05 - 3 . 5 0 . 075 - 1 . 75 polyethylene glycol 25 - 70 30 - 60 35 - 50 glycerin 25 - 70 30 - 60 35 - 50 flavors 0 . 1 - 10 1 - 8 3 - 6 c . clozepine lingual spray clozepine 0 . 5 - 30 1 - 20 10 - 15 ethanol 5 - 60 7 . 5 - 50 10 - 20 propylene glycol 5 - 30 7 . 5 - 20 10 - 15 polyethylene glycol 0 - 60 30 - 45 35 - 40 water 5 - 30 7 . 5 - 20 10 - 15 flavors 0 . 1 - 5 1 - 4 2 - 3 d . clozepine non - polar lingual spray with propellant clozepine 0 . 5 - 30 1 - 20 10 - 15 migylol 20 - 85 25 - 70 30 - 40 butanol 5 - 80 30 - 75 60 - 70 flavors 0 . 1 - 5 1 - 4 2 - 3 e . clozepine non - polar lingual spray without propellant clozepine 0 . 5 - 30 1 - 20 10 - 15 migylol 70 - 99 . 5 80 - 99 85 - 90 flavors 0 . 1 - 5 1 - 4 2 - 3 f . cyclobenzaprine non - polar lingual spray cyclobenzaprine ( base ) 0 . 5 - 30 1 - 20 10 - 15 migylol 20 - 85 25 - 70 30 - 40 iso - butane 15 - 80 30 - 75 60 - 70 flavors 0 . 1 - 5 1 - 4 2 - 3 g . dexfenfluramine hydrochloride lingual spray dexfenfluramine hcl 5 - 30 7 . 5 - 20 10 - 15 ethanol 5 - 60 7 . 5 - 50 10 - 20 propylene glycol 5 - 30 7 . 5 - 20 10 - 15 polyethylene glycol 0 - 60 30 - 45 35 - 40 water 5 - 30 7 . 5 - 20 10 - 15 flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . glyburide lingual spray glyburide 0 . 25 - 25 0 . 5 - 20 0 . 75 - 15 ethanol 5 - 60 − 7 . 5 - 50 10 - 20 propylene glycol 5 - 30 7 . 5 - 20 10 - 15 polyethylene glycol 0 - 60 30 - 45 35 - 40 water 2 . 5 - 30 5 - 20 6 - 15 flavors 0 . 1 - 5 1 - 4 2 - 3 b . glyburide non - polar bite capsule glyburide 0 . 01 - 10 0 . 025 - 7 . 5 0 . 1 - 4 olive oil 30 - 60 35 - 55 30 - 50 polyoxyethylated oleic 30 - 60 35 - 55 30 - 50 glycerides flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . zidovudine [ formerly called azidothymidine ( azt ) ( retrovir )] non - polar lingual spray zidovudine 10 - 50 15 - 40 25 - 35 soya oil 20 - 85 25 - 70 30 - 40 butane 15 - 80 30 - 75 60 - 70 flavors 0 . 1 - 5 1 - 4 2 - 3 b . erythromycin bite capsule bite capsule erythromycin 25 - 65 30 - 50 35 - 45 polyoxyethylene 5 - 70 30 - 60 45 - 55 glycol glycerin 5 - 20 7 . 5 - 15 10 - 12 . 5 flavors 1 - 10 2 - 8 3 - 6 c . ciprofloxacin hydrochloride bite capsule ciprofloxacin 25 - 65 35 - 55 40 - 50 hydrochloride glycerin 5 - 20 7 . 5 - 15 10 - 12 . 5 polyethylene glycol 120 - 75 30 - 65 40 - 60 d . zidovudine [ formerly called azidothymidine ( azt )( retrovir )] lingual spray zidovudine 10 - 50 15 - 40 25 - 35 water 30 - 80 40 - 75 45 - 70 ethanol 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 polyethylene 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 glycol flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . ondansetron hydrochloride lingual spray ondansetron 1 - 25 2 - 20 2 . 5 - 15 hydrochloride citric acid 1 - 10 2 - 8 2 . 5 - 5 monohydrate sodium citrate 0 . 5 - 5 1 - 4 1 . 25 - 2 . 5 dihydrate water 1 - 90 5 - 85 10 - 75 ethanol 5 - 30 7 . 5 - 20 9 . 5 - 15 propylene glycol 5 - 30 7 . 5 - 20 9 . 5 - 15 polyethylene glycol 5 - 30 7 . 5 - 20 9 . 5 - 15 flavors 1 - 10 3 - 8 5 - 7 . 5 b . dimenhydrinate bite capsule dimenhydrinate 0 . 5 - 30 2 - 25 3 - 15 glycerin 5 - 20 7 . 5 - 15 10 - 12 . 5 polyethylene glycol 45 - 95 50 - 90 55 - 85 flavors 1 - 10 2 - 8 3 - 6 c . dimenhydrinate polar lingual spray dimenhydrinate 3 - 50 4 - 40 5 - 35 water 5 - 90 10 - 80 15 - 75 ethanol 1 - 80 3 - 50 5 - 10 polyethylene glycol 1 - 80 3 - 50 5 - 15 sorbitol 0 . 1 - 5 0 . 2 - 40 0 . 4 - 1 . 0 aspartame 0 . 01 - 0 . 5 0 . 02 - 0 . 4 0 . 04 - 0 . 1 flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . cimetidine hydrochloride bite capsule cimetidine hcl 10 - 60 15 - 55 25 - 50 glycerin 5 - 20 7 . 5 - 15 10 - 12 . 5 polyethylene glycol 20 - 90 25 - 85 30 - 75 flavors 1 - 10 2 - 8 3 - 6 b . famotidine lingual spray famotidine 1 - 35 5 - 30 7 - 20 water 2 . 5 - 25 3 - 20 5 - 10 l - aspartic acid 0 . 1 - 20 1 - 15 5 - 10 polyethylene glycol 20 - 97 30 - 95 50 - 85 flavors 0 . 1 - 10 1 - 7 . 5 2 - 5 c . famotidine non - polar lingual spray famotidine 1 - 35 5 - 30 7 - 20 soya oil 10 - 50 15 - 40 15 - 20 butane1 5 - 80 30 - 75 45 - 70 polyoxyethylated 10 - 50 15 - 40 15 - 20 oleic glycerides flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . phenytoin sodium lingual spray phenytoin sodium 10 - 60 15 - 55 20 - 40 water 2 . 5 - 25 3 - 20 5 - 10 ethanol 5 - 30 7 . 5 - 20 9 . 5 - 15 propylene glycol 5 - 30 7 . 5 - 20 9 . 5 - 15 polyethylene glycol 5 - 30 7 . 5 - 20 9 . 5 - 15 flavors 1 - 10 3 - 8 5 - 7 . 5 b . phenytoin non - polar lingual spray phenytoin 5 - 45 10 - 40 15 - 35 migylol 10 - 50 15 - 40 15 - 20 butane 15 - 80 30 - 75 60 - 70 polyoxyethylated 10 - 50 15 - 40 15 - 20 oleic glycerides flavors 0 . 1 - 10 1 - 8 5 - 7 . 5 preferred most preferred amounts amount amount a . carboprost thromethamine lingual spray carboprost thromethamine 0 . 05 - 5 0 . 1 - 3 0 . 25 - 2 . 5 water 50 - 95 60 - 80 65 - 75 ethanol 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 polyethylene glycol 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 sodium chloride 1 - 20 3 - 15 4 - 8 flavors 0 . 1 - 5 1 - 4 2 - 3 ph is adjusted with sodium hydroxide and / or hydrochloric acid b . carboprost non - polar lingual spray carboprost 0 . 05 - 5 0 . 1 - 3 0 . 25 - 2 . 5 migylol 25 - 50 30 - 45 35 - 40 butane 5 - 60 10 - 50 20 - 35 polyoxyethylated 25 - 50 30 - 45 35 - 40 oleic glycerides flavors 0 . 1 - 10 1 - 8 5 - 7 . 5 most preferred amounts preferred amount amount a . carnitine as bite capsule ( contents are a paste ) carnitine fumarate 6 - 80 30 - 70 45 - 65 soya oil 7 . 5 - 50 10 - 40 12 . 5 - 35 soya lecithin 0 . 001 - 1 . 0 0 . 005 - 0 . 5 . 01 - 0 . 1 soya fats 7 . 5 - 50 10 - 40 12 . 5 - 35 flavors 1 - 10 2 - 8 3 - 6 b . valerian as lingual spray valerian extract 0 . 1 - 10 0 . 2 - 7 0 . 25 - 5 water 50 - 95 60 - 80 65 - 75 ethanol 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 polyethylene glycol 5 - 20 7 . 5 - 15 9 . 5 - 12 . 5 flavors 1 - 10 2 - 8 3 - 6 c . echinacea as bite capsule echinacea extract 30 - 85 40 - 75 45 - 55 soya oil 7 . 5 - 50 10 - 40 12 . 5 - 35 soya lecithin 0 . 001 - 1 . 0 0 . 005 - 0 . 5 . 01 - 0 . 1 soya fats 7 . 5 - 50 10 - 40 12 . 5 - 35 flavors 1 - 10 2 - 8 3 - 6 d . mixtures of ingredients magnesium oxide 15 - 40 20 - 35 25 - 30 chromium picolinate 0 . 01 - 1 . 0 0 . 02 - 0 . 5 . 025 - 0 . 75 folic acid . 025 - 3 . 0 0 . 05 - 2 . 0 0 . 25 - 0 . 5 vitamin b - 12 0 . 01 - 1 . 0 0 . 02 - 0 . 5 . 025 - 0 . 75 vitamin e 15 - 40 20 - 35 25 - 30 soya oil 10 - 40 12 . 5 - 35 15 - 20 soya lecithin 0 . 1 - 5 0 . 2 - 4 0 . 5 - 1 . 5 soya fat 10 - 40 15 - 35 17 . 5 - 20 a . diphenhydramine hydrochloride lingual spray most preferred amounts preferred amount amount diphenhydramine 3 - 50 4 - 40 5 - 35 hcl water 5 - 90 10 - 80 50 - 75 ethanol 1 - 80 3 - 50 5 - 10 polyethylene glycol 1 - 80 3 - 50 5 - 15 sorbitol 0 . 1 - 5 0 . 2 - 4 0 . 4 - 1 . 0 aspartame 0 . 01 - 0 . 5 0 . 02 - 0 . 4 0 . 04 - 0 . 1 flavors 0 . 1 - 5 1 - 4 2 - 3 most preferred amounts preferred amount amount a . isoproterenol hydrochloride as polar lingual spray isoproterenol 0 . 1 - 10 0 . 2 - 7 . 5 0 . 5 - 6 hydrochloride water 5 - 90 10 - 80 50 - 75 ethanol 1 - 80 3 - 50 5 - 10 polyethylene glycol 1 - 80 3 - 50 5 - 15 sorbitol 0 . 1 - 5 0 . 2 - 4 0 . 4 - 1 . 0 aspartame 0 . 01 - 0 . 5 0 . 02 - 0 . 4 0 . 04 - 0 . 1 flavors 0 . 1 - 5 1 - 4 2 - 3 b . terbutaline sulfate as polar lingual spray terbutaline sulfate 0 . 1 - 10 0 . 2 - 7 . 5 0 . 5 - 6 water 5 - 90 10 - 80 50 - 75 ethanol 1 - 10 2 - 8 2 . 5 - 5 sorbitol 0 . 1 - 5 0 . 2 - 4 0 . 4 - 1 . 0 aspartame 0 . 01 - 0 . 5 0 . 02 - 0 . 4 0 . 04 - 0 . 1 flavors 0 . 1 - 5 1 - 4 2 - 3 c . terbutaline as non - polar lingual spray terbutaline 0 . 1 - 10 0 . 2 - 7 . 5 0 . 5 - 6 migylol 25 - 50 30 - 45 35 - 40 isobutane 5 - 60 10 - 50 20 - 35 polyoxyethylated 25 - 50 30 - 45 35 - 40 oleic glycerides flavors 0 . 1 - 10 1 - 8 5 - 7 . 5 d . theophylline polar bite capsule theophylline 5 - 50 10 - 40 15 - 30 polyethylene glycol 20 - 60 25 - 50 30 - 40 glycerin 25 - 50 35 - 45 30 - 40 propylene glycol 25 - 50 35 - 45 30 - 40 flavors 0 . 1 - 5 1 - 4 2 - 3 e . albuterol sulfate as polar lingual spray albuterol 0 . 1 - 10 0 . 2 - 7 . 5 0 . 5 - 6 sulfate water 5 - 90 10 - 80 50 - 75 ethanol 1 - 10 2 - 8 2 . 5 - 5 sorbitol 0 . 1 - 5 0 . 2 - 4 0 . 4 - 1 . 0 aspartame 0 . 01 - 0 . 5 0 . 02 - 0 . 4 0 . 04 - 0 . 1 flavors 0 . 1 - 5 1 - 4 2 - 3 preferred most - preferred amount amount amount a . sulfonylurea glyburide 0 . 1 - 25 % 0 . 5 - 15 % 0 . 6 - 10 % ethanol 40 - 99 % 60 - 97 % 70 - 97 % water 0 . 01 - 5 % 0 . 1 - 4 % 0 . 2 - 2 % flavors 0 . 05 - 10 % 0 . 1 - 5 % 0 . 1 - 2 . 5 % propellant 2 - 10 % 3 - 5 % 3 - 4 % b . prostaglandin e ( vasodilator ) prostaglandin e 1 0 . 01 - 10 % 0 . 1 - 5 % 0 . 2 - 3 % ethanol 10 - 90 % 20 - 75 % 25 - 50 % propylene glycol 1 - 90 % 5 - 80 % 10 - 75 % water 0 . 01 - 5 % 0 . 1 - 4 % 0 . 2 - 2 % flavors 0 . 05 - 10 % 0 . 1 - 5 % 0 . 1 - 2 . 5 % propellant 2 - 10 % 3 - 5 % 3 - 4 % c . promethazine ( antiemetic , sleep inducer , and cns active amine ) promethazine 1 - 25 % 3 - 15 % 5 - 12 % ethanol 10 - 90 % 20 - 75 % 25 - 50 % propylene glycol 1 - 90 % 5 - 80 % 10 - 75 % water 0 . 01 - 5 % 0 . 1 - 4 % 0 . 2 - 2 % flavors 0 . 05 - 10 % 0 . 1 - 5 % 0 . 1 - 2 . 5 % propellant 2 - 10 % 3 - 5 % 3 - 4 % d . meclizine meclizine 1 - 25 % 3 - 15 % 5 - 12 % ethanol 1 - 15 % 2 - 10 % 3 - 6 propylene glycol 20 - 98 % 5 - 90 % 10 - 85 % water 0 . 01 - 5 % 0 . 1 - 4 % 0 . 2 - 2 % flavors 0 . 05 - 10 % 0 . 1 - 5 % 0 . 1 - 2 . 5 % propellant 2 - 10 % 3 - 5 % 3 - 4 % a . exemplary components for propellant free buccal spray formulations comprising propofol in a polar solvent preferred most preferred components amount ( w %) amount ( w %) amount ( w %) propofol 0 . 1 to 99 . 8 1 to 95 5 to 90 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate ethanol usp 0 . 05 to 98 . 7 1 to 75 5 to 60 1 . a propellant free buccal spray propofol formulation comprising propofol in a polar solvent contained the following : weight percent of components amount ( g ) composition ( w %) propofol 80 85 . 7 oleic acid 1 1 . 1 bitter mask 1 1 . 1 ascorbyl palmitate 2 2 . 1 ethanol usp 9 . 38 10 . 0 total 93 . 38 100 . 0 2 . a propellant free buccal spray propofol formulation comprising propofol in a polar solvent contained the following : weight percent of components amount ( g ) composition ( w %) propofol 90 95 . 3 oleic acid 1 1 . 1 bitter mask 1 1 . 1 ascorbyl palmitate 0 . 2 0 . 2 ethanol usp 2 . 21 2 . 3 total 94 . 41 100 . 0 b . exemplary components for buccal spray formulations comprising a propellant and propofol in a polar solvent preferred most preferred components amount ( w %) amount ( w %) amount ( w %) propofol 1 to 85 5 to 75 10 to 70 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate ethanol 1 to 85 5 to 75 10 to 60 butane 10 to 90 10 to 85 15 to 65 c . exemplary components for propellant free buccal spray formulations comprising propofol in a non - polar solvent preferred most preferred components amount ( w %) amount ( w %) amount ( w %) propofol 0 . 1 to 99 . 8 1 to 95 5 to 90 miglyol 810 0 . 05 to 98 . 7 1 to 75 5 to 60 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate d . exemplary components for buccal spray formulations comprising a propellant and propofol in a non - polar solvent preferred most preferred components amount ( w %) amount ( w %) amount ( w %) propofol 1 to 85 5 to 75 10 to 70 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate miglyol 810 1 to 85 5 to 75 10 to 60 butane 10 to 90 10 to 85 15 to 65 e . exemplary components for propellant free buccal spray formulation comprising propofol in a mixture of a polar and a non - polar solvents preferred most preferred components amount ( w %) amount ( w %) amount ( w %) propofol 0 . 1 to 99 . 8 1 to 95 5 to 90 miglyol 810 0 . 1 to 80 0 . 5 to 75 1 to 60 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate ethanol usp 0 . 05 to 98 . 7 1 to 75 5 to 60 1 . a propellant free buccal spray formulation comprising propofol in a mixture of polar and non - polar solvents contained the following : weight percent of components amount ( g ) composition ( w %) propofol 20 22 . 3 miglyol 810 40 44 . 6 oleic acid 1 1 . 1 bitter mask 1 1 . 1 ascorbyl palmitate 0 . 4 0 . 4 ethanol usp 27 . 2 30 . 4 total 89 . 6 100 . 0 samples of this buccal spray formulation were tested to see if exposure of the samples to long - term stability conditions as well as accelerated stability conditions affected certain chemical and physical properties of the samples . the samples were tested using commercially - available single dose actuators . long term stability conditions were defined as 25 ± 2 degrees centigrade and 60 ± 5 % relative humidity . accelerated stability conditions were defined as 40 ± 2 degrees centigrade and 75 ± 5 % relative humidity . the samples were stored both in horizontal and upright orientations . the spray volumes , content , uniformity , pattern , angle and droplet size distribution of samples were determined at one month after imposing both long term and accelerated stability conditions on the samples . each assay was performed 5 times , except for droplet size distribution which was performed 15 times . the spray parameters were defined to be within specification if the coefficient of variation from the base line was 5 % or less . it was determined that the tested physical and chemical properties remained within specification after exposure of the samples to the long - term and accelerated stability conditions . 2 . a propellant free buccal spray propofol formulation comprising propofol in a mixture of polar and non - polar solvents contained in the following : weight percent of components amount ( g ) composition ( w %) propofol 60 64 . 5 miglyol 810 20 21 . 5 oleic acid 1 1 . 1 bitter mask 1 1 . 1 ascorbyl palmitate 0 . 2 0 . 2 ethanol usp 10 . 78 11 . 6 total 92 . 98 100 . 0 f . exemplary components for buccal spray formulations comprising a propellant and propofol in a mixture of polar and non - polar solvents preferred most preferred amount components amount ( w %) amount ( w %) ( w %) propofol 1 to 80 5 to 75 10 to 60 oleic acid 0 . 01 to 5 0 . 5 to 4 1 to 2 flavoring 0 . 01 to 5 0 . 5 to 4 1 to 2 agent / taste mask ascorbyl 0 . 01 to 20 0 . 5 to 10 1 to 2 palmitate miglyol 810 1 to 80 2 to 75 10 to 60 ethanol 2 to 80 5 to 75 10 to 60 butane 10 to 90 10 to 85 15 to 65
buccal aerosol sprays using polar and / or non - polar solvents have now been developed which provide propofol for rapid absorption through the oral mucosa , resulting in fast onset of effect . the buccal polar compositions of the invention comprise formulation i : propofol , a polar solvent and an optional flavoring agent ; formulation ii : propofol , a polar solvent , a propellant , and an optionally flavoring agent ; formulation iii : propofol , a non - polar solvent , and an optional flavoring agent ; formulation iv : propofol , a non - polar solvent , a propellant , and an optional flavoring agent ; formulation v : propofol , a mixture of a polar solvent and a non - polar solvent , and an optional flavoring agent ; and formulation vi : propofol , a mixture of a polar solvent and a non - polar solvent , a propellant , and an optional flavoring agent .